Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Net Income towards Common Stockholders (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Net Income towards Common Stockholders data on record, last reported at -$13.1 million in Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders rose 56.68% year-over-year to -$13.1 million; the TTM value through Sep 2025 reached $79.3 million, up 186.31%, while the annual FY2024 figure was -$63.7 million, 17.53% down from the prior year.
  • Net Income towards Common Stockholders reached -$13.1 million in Q3 2025 per ABEO's latest filing, down from $113.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $113.7 million in Q2 2025 and bottomed at -$46.7 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$9.5 million, with a median of -$13.1 million recorded in 2025.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 247.25% in 2024, then soared 945.23% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$46.7 million in 2021, then skyrocketed by 84.79% to -$7.1 million in 2022, then plummeted by 133.8% to -$16.6 million in 2023, then skyrocketed by 44.22% to -$9.3 million in 2024, then crashed by 41.49% to -$13.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$13.1 million in Q3 2025, $113.7 million in Q2 2025, and -$12.0 million in Q1 2025.